X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
melanoma (10) 10
ipilimumab (8) 8
oncology (7) 7
immunology (5) 5
index medicus (5) 5
overall survival (5) 5
best overall response (4) 4
ctla-4 variants (4) 4
efficacy (4) 4
humans (4) 4
predictive/prognostic factor (4) 4
adult (3) 3
adverse events (3) 3
aged (3) 3
association (3) 3
cancer (3) 3
chemotherapy (3) 3
immunotherapy (3) 3
middle aged (3) 3
neoplasm metastasis (3) 3
treatment outcome (3) 3
aged, 80 and over (2) 2
antibodies, monoclonal - administration & dosage (2) 2
biomarkers (2) 2
body mass index (2) 2
care and treatment (2) 2
ctla-4 protein (2) 2
disease (2) 2
drug administration schedule (2) 2
drug therapy (2) 2
elderly-patients (2) 2
expanded access programme (2) 2
female (2) 2
male (2) 2
melanoma - drug therapy (2) 2
melanoma - pathology (2) 2
metastases (2) 2
metastasis (2) 2
metastatic melanoma (2) 2
mucosal (2) 2
neoplasms. tumors. oncology. including cancer and carcinogens (2) 2
nivolumab (2) 2
patients (2) 2
predictive (2) 2
prognostic factor (2) 2
safety (2) 2
therapy (2) 2
usage (2) 2
young adult (2) 2
1st-line treatment (1) 1
adenocarcinoma - genetics (1) 1
adipose-tissue (1) 1
advanced melanoma (1) 1
analysis (1) 1
anti-pd-1 (1) 1
anti-pd-1/pd-l1 (1) 1
anti-programmed death-1 (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal, humanized (1) 1
antibody (1) 1
antineoplastic agents, immunological - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
anti‐programmed death‐1 (1) 1
autoimmune disease (1) 1
autoimmunity (1) 1
best overall response; ctla-4 variants; ipilimumab; melanoma; overall survival; predictive/prognostic factor; immunology and allergy; immunology (1) 1
best response (1) 1
bevacizumab (1) 1
biochemotherapy (1) 1
biomarkers, tumor - blood (1) 1
biomarkers, tumor - metabolism (1) 1
blockade (1) 1
bmi (1) 1
braf mutations (1) 1
camptothecin - administration & dosage (1) 1
camptothecin - analogs & derivatives (1) 1
cancer patients (1) 1
cancer research (1) 1
capecitabine (1) 1
cdkn2 (1) 1
chemotherapy, combination (1) 1
chronomodulated infusion (1) 1
clinical outcomes (1) 1
cohort studies (1) 1
colorectal cancer (1) 1
colorectal neoplasms - drug therapy (1) 1
continuity of care (1) 1
correction (1) 1
cpg islands (1) 1
criteria (1) 1
ctla-4 antigen - blood (1) 1
ctla-4 antigen - metabolism (1) 1
cutaneous melanoma (1) 1
cyclin-dependent kinase inhibitor p16 - genetics (1) 1
cytotoxicity (1) 1
dacarbazine (1) 1
diarrhea (1) 1
digestive tract (1) 1
disease progression (1) 1
disease-free survival (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e15021 - e15021
Journal Article
Frontiers in Endocrinology, ISSN 1664-2392, 11/2019, Volume 10
Insulin resistance and obesity are suggested to have a key role in the molecular pathogenesis of various disorders, including several malignancies. Moreover,... 
cutaneous melanoma | HOMA-IR | QUICKI | insulin resistance | body mass index
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 50, Issue 1, pp. 121 - 127
Abstract Background Mucosal melanoma is an extremely rare and aggressive malignancy that often remains undetected until it reaches an advanced stage, when... 
Hematology, Oncology and Palliative Medicine | Expanded access programme | Efficacy | Metastatic melanoma | Safety | Mucosal | Ipilimumab | SURVIVAL | BIOCHEMOTHERAPY | PHASE-II | OPEN-LABEL | DACARBAZINE | CHEMOTHERAPY | KIT MUTATION | ONCOLOGY | BRAF MUTATIONS | IMATINIB MESYLATE
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 01/2019, Volume 68, Issue 1, pp. 97 - 107
Journal Article
The Oncologist, ISSN 1083-7159, 06/2019, Volume 24, Issue 6, pp. e327 - e337
Background Patients with a history of autoimmune diseases (AIDs) have not usually been included in clinical trials with immune checkpoint inhibitors. Materials... 
Autoimmune disease | Immune checkpoint inhibitors | Immunotherapy | Performance status | Anti‐programmed death‐1 | Sex | Anti-programmed death-1 | CRITERIA | MANAGEMENT | EFFICACY | IMMUNE-CHECKPOINT INHIBITORS | THERAPY | ONCOLOGY | ADVANCED MELANOMA | SEX-DIFFERENCES | ELDERLY-PATIENTS | ASSOCIATION | ADVERSE EVENTS
Journal Article
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 02/2019, Volume 7, Issue 1, pp. 57 - 11
BackgroundRecent evidence suggested a potential correlation between overweight and the efficacy of immune checkpoint inhibitors (ICIs) in cancer... 
Anti-PD-1/PD-L1 | Obesity | Immunotherapy | BMI | Cancer | Overweight | Anti-PD-1 | IMMUNOLOGY | CHEMOTHERAPY | FEATURES | MELANOMA | ONCOLOGY | INFLAMMATION | PD-L1 | NIVOLUMAB | ELDERLY-PATIENTS | ASSOCIATION | ADVERSE EVENTS | ADIPOSE-TISSUE | Body mass index | Treatment outcome | Cancer patients | Care and treatment | Usage | Analysis | Health aspects | Studies | Lung cancer | Melanoma | Response rates | Systematic review | Patients | Clinical outcomes | Tumors
Journal Article
Journal Article
Journal Article
JOURNAL OF TRANSLATIONAL MEDICINE, 11/2019, Volume 17, Issue 1, pp. 1 - 6
Background Fatigue was reported as the most common any-grade adverse event (18.3%), and the most common grade 3 or higher immune-related adverse event (irAE)... 
MEDICINE, RESEARCH & EXPERIMENTAL | Immune-related adverse events | MELANOMA | PD-L1 inhibitors | Immunotherapy | Fatigue | NIVOLUMAB | PD-1 | IL-6 | T-CELL TOLERANCE | IPILIMUMAB | Cancer | PD-1/PD-L1 inhibitors
Journal Article
AboutOpen, ISSN 2465-2628, 06/2019, Volume 6, Issue 1, pp. 39 - 47
Introduction: The Integrated Care Pathway (ICP) represents a multidisciplinary outline of anticipated care, placed in an appropriate timeframe, to support... 
Continuity of care | Integrated Care Pathway | Melanoma | Patient care
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.